



DIAGNOSTIC AUTOMATION, INC.

23961 Craftsman Road, Suite E/F, Calabasas, CA 91302

Tel: (818) 591-3030 Fax: (818) 591-8383

onestep@rapidtest.com

technicalsupport@rapidtest.com

www.rapidtest.com

IVD



See external label



2°C-8°C



Σ=96 tests

REF

#2042-6

Dihydrotestosterone (DHT) ELISA

Cat. No. 2042-6

INTENDED USE

For the direct quantitative determination of Dihydrotestosterone by enzyme immunoassay in human serum. For in vitro diagnostic use only.

PRINCIPLE OF THE TEST

The principle of the following enzyme immunoassay test follows the typical competitive binding scenario. Competition occurs between an unlabeled antigen (present in standards, control and patient samples) and an enzyme-labelled antigen (conjugate) for a limited number of antibody binding sites on the microwell plate. The washing and decanting procedures remove unbound materials. After the washing step, the enzyme substrate is added. The enzymatic reaction is terminated by addition of the stopping solution. The absorbance is measured on a microtiter plate reader. The intensity of the colour formed is inversely proportional to the concentration of DHT in the sample. A set of standards is used to plot a standard curve from which the amount of DHT in patient samples and controls can be directly read.

CLINICAL APPLICATIONS

5 α -dihydrotestosterone (DHT) is a steroid similar to testosterone and androstenedione, which belong to a class called androgens. DHT is a C19 steroid and possesses androgenic activity. The bulk of androgen production takes place mainly in the Leydig cells of the testes. Androgens circulate in the blood bound to proteins, especially sex hormone binding globulin (SHBG) and albumin. A trace amount of these steroids circulate in the unbound form in the blood and are referred to as the free fractions. DHT has at least three times the binding affinity for SHBG than testosterone. In males about 70% of DHT is derived from peripheral conversion of testosterone, while in females most of the DHT is derived from androstenedione. The major organ to neutralize androgens is the liver. Therefore in the liver the steroid hormones undergo structural modifications that are generally regarded as prerequisites for their biological inactivation. Some metabolites are formed and some are returned to the circulation before renal excretion. Therefore, elimination of steroids from the body is done through the urine.

Clinical Trends:

- In Klinefelter's syndrome the DHT level is much lower than that found in normal men.
- In idiopathic hirsutism about 40% of the patients have an increased level of DHT.
- In polycystic ovaries (PCO) about 35% of the patients have an increased DHT level.
- The DHT level in young people is much higher than those found in normal older people, hence androgen production increases at puberty which gives rise to masculinizing characteristics. It has been demonstrated that the human testes produce DHT, which appears to originate in the seminiferous tubules. Therefore in tubular damage the production of DHT is impaired, which causes a decrease in the levels of plasma DHT (patients with germinal cell aplasia and azoospermia).
- There is a very low level of plasma DHT in patients with anorchia.

- It has been reported that in some prostate cancer (especially in stage D) the determination of DHT could be useful in predicting the response to anti-androgen therapy.

PROCEDURAL CAUTIONS AND WARNINGS

1. Users should have a thorough understanding of this protocol for the successful use of this kit. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
2. Control materials or serum pools should be included in every run at a high and low level for assessing the reliability of results.
3. When the use of water is specified for dilution or reconstitution, use deionized or distilled water.
4. In order to reduce exposure to potentially harmful substances, gloves should be worn when handling kit reagents and human specimens.
5. All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. Avoid repeated freezing and thawing of reagents and specimens.
6. A calibrator curve must be established for every run.
7. The control should be included in every run and fall within established confidence limits.
8. Improper procedural techniques, imprecise pipetting, incomplete washing as well as improper reagent storage may be indicated when assay values for the control do not reflect established ranges.
9. When reading the microplate, the presence of bubbles in the microwells will affect the optical densities (ODs). Carefully remove any bubbles before performing the reading step.
10. The substrate solution (TMB) is sensitive to light and should remain colourless if properly stored. Instability or contamination may be indicated by the development of a blue colour, in which case it should not be used.
11. When dispensing the substrate and stopping solution, do not use pipettes in which these liquids will come into contact with any metal parts.
12. To prevent contamination of reagents, use a new disposable pipette tip for dispensing each reagent, sample, standard and control.
13. Do not mix various lot numbers of kit components within a test and do not use any component beyond the expiration date printed on the label.
14. Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.

LIMITATIONS

1. All the reagents within the kit are calibrated for the direct determination of DHT in human serum. The kit is not calibrated for the determination of DHT in saliva, plasma or other specimens of human or animal origin.
2. Do not use grossly hemolyzed, grossly lipemic, icteric or improperly stored serum.
3. Any samples or control sera containing azide or thimerosal are not compatible with this kit, as they may lead to false results.
4. Only calibrator A may be used to dilute any high serum samples. The use of any other reagent may lead to false results.
5. The results obtained with this kit should never be used as the sole basis for a clinical diagnosis. For example, the occurrence of heterophilic antibodies in patients regularly exposed to animals or animal products has the potential of causing interferences in immunological tests. Consequently, the clinical diagnosis should include all aspects of a patient's background including the frequency of exposure to animals/products if false results are suspected.

SAFETY CAUTIONS AND WARNINGS POTENTIAL BIOHAZARDOUS MATERIAL

Human serum that may be used in the preparation of the standards and control has been tested and found to be non-reactive for Hepatitis B surface antigen and has also been tested for the presence of antibodies to HCV and Human Immunodeficiency Virus (HIV) and found to be negative. However no test method can offer complete assurance that HIV, HCV and Hepatitis B virus or any infectious agents are absent. The

reagents should be considered a potential biohazard and handled with the same precautions as applied to any blood specimen.

CHEMICAL HAZARDS

Avoid contact with reagents containing TMB, hydrogen peroxide and sulfuric acid. If contacted with any of these reagents, wash with plenty of water. TMB is a suspected carcinogen.

SPECIMEN COLLECTION AND STORAGE

Approximately 0.2 ml of serum is required per duplicate determination. Collect 4-5 ml of blood into an appropriately labelled tube and allow it to clot. Centrifuge and carefully remove the serum layer. Store at 4°C for up to 24 hours or at -10°C or lower if the analyses are to be done at a later date. Consider all human specimens as possible biohazardous materials and take appropriate precautions when handling.

SPECIMEN PRETREATMENT

This assay is a direct system; no specimen pretreatment is necessary.

REAGENTS AND EQUIPMENT NEEDED BUT NOT PROVIDED

1. Precision pipettes to dispense 50, 100, 150 and 300 µl
2. Disposable pipette tips
3. Distilled or deionized water
4. Plate shaker
5. Microwell plate reader with a filter set at 450nm and an upper OD limit of 3.0 or greater* (see assay procedure step 10).

REAGENTS PROVIDED

1. Rabbit Anti-DHT Antibody Coated Microwell Plate-Break Apart Wells - Ready To Use.

Contents: One 96 well (12x8) polyclonal antibody-coated microwell plate in a resealable pouch with desiccant.

Storage: Refrigerate at 2-8°C

Stability: 12 months or as indicated on label.

2. Dihydrotestosterone-Horseradish Peroxidase (HRP) Conjugate Concentrate - Requires Preparation.

Contents: DHT-HRP conjugate in a protein-based buffer with a non-mercury preservative.

Volume: 200 µl/vial

Storage: Refrigerate at 2-8°C

Stability: 12 months or as indicated on label.

Preparation: Dilute 1:100 in assay buffer before use (eg. 20 µl of HRP in 2 ml of assay buffer). If the whole plate is to be used dilute 120 µl of HRP in 12ml of assay buffer. Discard any that is left over.

3. Dihydrotestosterone Calibrators - Ready To Use.

Contents: Six vials containing DHT in a protein-based buffer with a non-mercury preservative. Prepared by spiking buffer with a defined quantity of DHT. *Listed below are approximate concentrations, please refer to vial labels for exact concentrations.

| Calibrator | Concentration | Volume/Vial |
|-------------------|----------------------|--------------------|
| Calibrator A | 0 pg/ml | 2.0 ml |
| Calibrator B | 25 pg/ml | 0.6 ml |
| Calibrator C | 100 pg/ml | 0.6 ml |
| Calibrator D | 500 pg/ml | 0.6 ml |
| Calibrator E | 1000 pg/ml | 0.6 ml |
| Calibrator F | 2500 pg/ml | 0.6 ml |

Storage: Refrigerate at 2-8°C

Stability: 12 months in unopened vials or as indicated on label. Once opened, the standards should be used within 14 days or aliquoted and stored frozen. Avoid multiple freezing and thawing cycles.

4. Control - Ready To Use.

Contents: One vial containing DHT in a protein-based buffer with a non-mercury preservative. Prepared by spiking buffer with a defined quantity of DHT. Refer to vial label for expected value and acceptable range.

Volume: 0.6 ml/vial

Storage: Refrigerate at 2-8°C

Stability: 12 months in unopened vial or as indicated on label. Once opened, the control should be used within 14 days or aliquoted and stored frozen. Avoid multiple freezing and thawing cycles.

5. Wash Buffer Concentrate - Requires Preparation.

Contents: One bottle containing buffer with a non-ionic detergent and a non-mercury preservative.

Volume: 50 ml/bottle

Storage: Refrigerate at 2-8°C

Stability: 12 months or as indicated on label.

Preparation: Dilute 1:10 in distilled or deionized water before use. If the whole plate is to be used dilute 50 ml of the wash buffer concentrate in 450 ml of water.

6. Assay Buffer - Ready To Use.

Contents: One vial containing a protein-based buffer with a non-mercury preservative.

Volume: 15 ml/vial

Storage: Refrigerate at 2-8°C

Stability: 12 months or as indicated on label.

7. TMB Substrate - Ready To Use.

Contents: One bottle containing tetramethylbenzidine and hydrogen peroxide in a non-DMF or DMSO containing buffer.

Volume: 16 ml/bottle

Storage: Refrigerate at 2-8°C

Stability: 12 months or as indicated on label.

8. Stopping Solution - Ready To Use.

Contents: One vial containing 1M sulfuric acid.

Volume: 6 ml/vial

Storage: Refrigerate at 2-8°C

Stability: 12 months or as indicated on label.

ASSAY PROCEDURE

Specimen Pretreatment: None.

All reagents must reach room temperature before use. Calibrators, controls and specimen samples should be assayed in duplicate. Once the procedure has been started, all steps should be completed without interruption.

1. Prepare working solutions of the DHT-HRP conjugate and wash buffer.
2. Remove the required number of microwell strips. Reseal the bag and return any unused strips to the refrigerator.
3. Pipette 50 µl of each calibrator, control and specimen sample into correspondingly labelled wells in duplicate.

4. Pipette 100 µl of the conjugate working solution into each well (We recommend using a multichannel pipette).
5. Incubate on a plate shaker (approximately 200rpm) for 1 hour at room temperature.
6. Wash the wells 3 times with 300 µl of diluted wash buffer per well and tap the plate firmly against absorbent paper to ensure that it is dry (The use of a washer is recommended).
7. Pipette 150 µl of TMB substrate into each well at timed intervals.
8. Incubate on a plate shaker for 10-15 minutes at room temperature (or until calibrator A attains dark blue colour for desired OD).
9. Pipette 50 µl of stopping solution into each well at the same timed intervals as in step 7.
10. Read the plate on a microwell plate reader at 450nm within 20 minutes after addition of the stopping solution.

* If the OD exceeds the upper limit of detection or if a 450nm filter is unavailable, a 405 or 415nm filter may be substituted. The optical densities will be lower, however, this will not affect the results of patient/control samples.

CALCULATIONS


1. Calculate the mean optical density of each calibrator duplicate.
2. Draw a calibrator curve on semi-log paper with the mean optical densities on the Y-axis and the calibrator concentrations on the X-axis. If immunoassay software is being used, a 4-parameter curve is recommended.
3. Calculate the mean optical density of each unknown duplicate.
4. Read the values of the unknowns directly off the calibrator curve.
5. If a sample reads more than 2500 pg/ml then dilute it with calibrator A at a dilution of no more than 1:8. The result obtained should be multiplied by the dilution factor.

TYPICAL TABULATED DATA

| Calibrator | OD 1 | OD 2 | Mean OD | Value (pg/ml) |
|------------|-------|-------|---------|---------------|
| A | 2.320 | 2.279 | 2.300 | 0 |
| B | 1.976 | 1.928 | 1.952 | 25 |
| C | 1.058 | 1.077 | 1.068 | 100 |
| D | 0.359 | 0.354 | 0.357 | 500 |
| E | 0.222 | 0.205 | 0.214 | 1000 |
| F | 0.131 | 0.128 | 0.130 | 2500 |
| Unknown | 0.515 | 0.507 | 0.511 | 300 |

TYPICAL CALIBRATOR CURVE

Sample curve only. Do not use to calculate results.



PERFORMANCE CHARACTERISTICS

SENSITIVITY

The lower detection limit is calculated from the standard curve by determining the resulting concentration of the mean OD of Calibrator A (based on 10 replicate analyses) minus 2 SD. Therefore, the sensitivity of the Direct Dihydrotestosterone ELISA kit is 6.0 pg/ml.

SPECIFICITY (CROSS REACTIVITY)

The following compounds were tested for cross-reactivity with the Direct Dihydrotestosterone ELISA kit with dihydrotestosterone cross-reacting at 100%.

| Steroid | %Cross Reactivity |
|-------------------------------|-------------------|
| Dihydrotestosterone | 100 |
| Testosterone | 8.7 |
| 5 β Dihydrotestosterone | 2.0 |
| Androstenedione | 0.2 |

The following steroids were tested but cross-reacted at less than 0.01%: Dehydroepiandrosterone Sulfate, 17 β -Estradiol, Estriol, Estrone, Progesterone, 17-OH Progesterone, Cortisol, and Pregnenolone.

INTRA-ASSAY PRECISION

Three samples were assayed ten times each on the same calibrator curve. The results (in pg/ml) are tabulated below:

| Sample | Mean | SD | CV% |
|--------|---------|-------|------|
| 1 | 236.74 | 26.89 | 11.4 |
| 2 | 869.03 | 47.41 | 5.46 |
| 3 | 1008.14 | 39.36 | 3.90 |

INTER-ASSAY PRECISION

Three samples were assayed ten times over a period of four weeks. The results (in pg/ml) are tabulated below:

| Sample | Mean | SD | CV% |
|--------|---------|-------|------|
| 1 | 280.88 | 34.07 | 12.1 |
| 2 | 721.40 | 54.20 | 7.5 |
| 3 | 1025.41 | 60.45 | 5.9 |

RECOVERY

Spiked samples were prepared by adding defined amounts of DHT to three patient serum samples. The results (in pg/ml) are tabulated below:

| Sample | Obs.Result | Exp.Result | Recovery% |
|------------|------------|------------|-----------|
| 1 Unspiked | 290.54 | - | - |
| +117.53 | 361.51 | 408.07 | 88.6 |
| +235.06 | 501.66 | 525.60 | 95.4 |
| +470.13 | 744.81 | 760.67 | 97.9 |
| 2 Unspiked | 324.75 | - | - |
| +117.53 | 389.43 | 442.29 | 88.0 |
| +235.06 | 505.23 | 559.81 | 90.3 |
| +470.13 | 712.44 | 794.88 | 89.6 |
| 3 Unspiked | 720.11 | - | - |
| +117.53 | 758.13 | 837.64 | 90.5 |
| +235.06 | 856.46 | 955.17 | 89.7 |
| +470.13 | 1013.61 | 1190.24 | 85.1 |

LINEARITY

Three patient serum samples were diluted with calibrator A. The results (in pg/ml) are tabulated below:

| Sample | Obs.Result | Exp.Result | Recovery% |
|--------|------------|------------|-----------|
| 1 | 340.67 | - | - |
| 1:2 | 165.35 | 170.34 | 97.1 |
| 1:4 | 95.39 | 85.17 | 112.0 |
| 1:8 | 48.47 | 42.58 | 113.8 |
| 2 | 1086.01 | - | - |
| 1:2 | 508.58 | 543.00 | 93.7 |
| 1:4 | 232.11 | 271.50 | 85.5 |
| 1:8 | 114.95 | 135.75 | 84.7 |
| 3 | 1313.21 | - | - |
| 1:2 | 612.98 | 656.61 | 93.4 |
| 1:4 | 318.63 | 328.30 | 97.1 |
| 1:8 | 134.98 | 164.15 | 82.2 |

COMPARATIVE STUDIES

The Direct Dihydrotestosterone ELISA kit (Kit A) was compared with a competitors coated tube RIA kit (Kit B). The results (in pg/ml) are tabulated below:

| Group | N | Kit A Mean | Kit B Mean |
|---------|----|------------|------------|
| Females | 10 | 95.5 | 99.0 |
| Males | 10 | 280.0 | 252.0 |

EXPECTED NORMAL VALUES

As for all clinical assays each laboratory should collect data and establish their own range of expected normal values.

| Group | Range (pg/ml) |
|----------------|---------------|
| Females: | |
| Premenopausal | 24-368 |
| Postmenopausal | 10-181 |
| Males | 250-990 |

REFERENCES

1. Bassett, R.M., A simple chromatographic method for the radioimmunoassay of four androgenic steroids. *Medical Laboratory Sciences*, 37:31, 1980.
2. Baxendale, P.M., et al., Plasma and salivary androstenedione and dihydrotestosterone in women with hyperandrogenism. *Clinical Endocrinology*, 18:447, 1983.
3. Brooks, R.V., Androgens. *Physiology and Pathology* In: Makin, H.L. J., ed., *Biochemistry of Steroid Hormones*, 2nd ed., Oxford Blackwell Scientific Publications, 565:1984.
4. Cameron, E.H.D., In proceedings of the fifth tenovousworkshop, *Steroid Immunoassay*, ed., Cameron, E.H.D., et al., Alpha Omega Publishing Cordiff, 1975.
5. Dunn, J.F., et al, Transport of Steroid Hormones: Binding of 21 endogenous steroids to both SHBG and CBG in human plasma. *J. Clin. Endocr. Metab.* 53:58, 1981.
6. Hammond, G.L., et al, The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood. *J. Clin. Endocr. Metab.* 45:16, 1977.
7. Ito, T., et al, Dihydrotestosterone in human peripheral plasma. *J. Clin. Endocr.* 31:362, 1970.
8. Mean, F., et al, Study of the binding of dihydrotestosterone, testosterone and oestradiol with sex hormone binding globulin. *Clinica Cemica Alta* 80:171, 1977.
9. Mooradian, A.D., et al, The biological actions of androgens. *Endocr. Rev.* 8:1-28, 1987.
10. Pazzagli, M., et al, Radioimmunoassay of plasma dihydrotestosterone in normal and hypogonadal men. *Clin. Endocr.* 82:380, 1976.

11. Wakelin, K., et al, Relationship of 5 β dihydrotestosterone and 5 α dihydrotestosterone to testosterone in health and disease. J. Endocrinol. 87:450, 1980.
12. Wang, C., et al, Solitary androgens in hirsutism: Are they of use in routine evaluation. Ann. Clin. Biochem. 23: 590, 1986.
13. Kricka, L.J., Human anti-animal antibody interferences in immunological assays. Clin. Chemistry 45:7, 1999.
14. Check, J.H., et al, Falsely elevated steroidal assay levels related to heterophile antibodies against various animal species. Gynecol Obstet Invest 40:139-140, 1995.



DIAGNOSTIC AUTOMATION, INC.

23961 Craftsman Road, Suite E/F, Calabasas, CA 91302

Tel: (818) 591-3030 Fax: (818) 591-8383

ISO 13485-2003

Effective Date: 4-10-06